Quality of life and outcomes of patients operated on for glioblastoma Authors: Haman Nassourou Oumarou, Foka Tacsing Bolivers Kahn, Anu Ronaldo Fonju, Ghislain Guea Ngbwa, Djientcheu Vincent De Paul Published: 2026 ABSTRACT Background: Glioblastoma is the most common and aggressive primary malignant brain tumor in adults, with a poor prognosis despite multimodal treatment. This study aimed to describe the diagnostic aspects, therapeutic strategies, quality of life (QoL), and outcomes of patients operated on for glioblastoma at the Yaoundé General Hospital.Methods: This was a retrospective cohort study conducted at the Yaoundé General Hospital. Included were 32 patients who underwent surgery for glioblastoma with histological evidence from January 2018 to June 2025. Data were collected from medical records and analyzed using the Statistical Packages for the Social Sciences version 20. Comparisons between groups were performed using the Chi-square test or Student’s t-test as appropriate. Survival distributions were compared using the Kaplan–Meier method and the log-rank test. Statistical significance was set at P < 0.05, and 95% confidence intervals were calculated for the main estimates. QoL was assessed using the Karnofsky and European Organization for Research and Treatment of Cancer QoL Questionnaire-C30 scores. Both assessments were performed during postoperative follow-up visits, specifically between the 1st and the 6th month after surgery. When available, preoperative Karnofsky scores recorded in medical files were also reviewed to assess functional improvement after surgery. Factors associated with QoL and outcomes were identified, and P < 0.05 was considered significant. Overall survival was defined as the time interval between the date of histopathological confirmation of glioblastoma and the date of death or last follow-up.Results: Thirty-two patients were included, with a median age of 47.50 years (17.75; 59.75), a mean age of 42.9 ± 13.8 years, and a female predominance (65.6%). The most common presenting symptom was neurologic deficit (68.8%). Magnetic resonance imaging was the main diagnostic modality (59.4%), and the tumor was most often located in the temporal lobe (30.8%). Surgery alone was performed in 56.3% of cases, whereas 25% received surgery followed by radiochemotherapy. The average overall survival was 10.2 months, increasing to 13.4 months in patients who received the full multimodal treatment. QoL scores were also better in this group. Age >60 was found to be significantly associated with poor outcomes.Conclusion: Glioblastoma affects all ages in our setting. Combined therapeutic strategies, especially the addition of radiochemotherapy after surgery, were associated with longer survival and better QoL. Multidisciplinary management remains essential to improve outcomes. INTRODUCTION Glioblastoma multiforme (GBM) is the most common and most aggressive primary malignant brain tumor in adults, accounting for approximately 15% of all primary intracranial neoplasms and nearly 50% of gliomas worldwide.[8,11]According to recent estimates, the global incidence of GBM ranges from 3.2 to 4.7 per 100,000 population per year, with higher rates reported in Western countries.[2-16] In SubSaharan Africa, accurate epidemiological data are scarce due to underdiagnosis, delayed imaging, and limited access to neuropathological confirmation.[3] Histologically, GBM is classified as a grade IV astrocytoma under the 2021 World Health Organization (WHO) classification of central nervous system tumors.[20] It is characterized by rapid cellular proliferation, diffuse infiltration, angiogenesis, and necrosis.[7] Molecular markers such as isocitrate dehydrogenase (IDH) mutation and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation are now integral to diagnosis and prognosis.[13] Clinically, GBM presents most commonly with signs of increased intracranial pressure, motor deficits, and seizures.[9] Without treatment, survival rarely exceeds a few months. Even with optimal management – maximal safe resection followed by radiotherapy and concomitant and adjuvant temozolomide, known as the Stupp protocol – median survival remains limited to 12–15 months.[25] In our context at the Yaoundé General Hospital, GBM accounted for 5.1% of all intracranial tumors operated during the study period, a figure consistent with findings previously reported by Djientcheu et al. in the Central Hospital of Yaoundé.[3] Despite evidence supporting the benefit of multimodal management, access to radiotherapy, chemotherapy, and molecular testing remains highly constrained in many low-income countries, including Cameroon. These limitations can compromise both survival outcomes and quality of life (QoL) in affected patients.[24] This study aimed to describe the diagnostic patterns, therapeutic strategies, survival outcomes, and QoL of patients operated on for glioblastoma at the Yaoundé General Hospital. MATERIALS AND METHODS Study design and setting This study was a retrospective cohort study including patients who underwent surgical management for histologically confirmed glioblastoma between January 2018 and June 2025, conducted in the Department of Neurosurgery at the Yaoundé General Hospital, a first-category referral hospital within the Cameroonian health system. The hospital is located in Yaoundé, in the Djoungolo Health District, Ngousso Health Area. The neurosurgery department is managed by a professor of neurosurgery and a consultant neurosurgeon, assisted by residents, interns, a general practitioner, a ward matron, nurses, and support staff. The department has a total capacity of 25 hospital beds distributed across seven wards. This study was designed as a retrospective cohort study. However, QoL assessments using the European Organization for Research and Treatment of Cancer QoL Questionnaire (EORTC QLQ-C30) questionnaires were administered through direct interviews during routine postoperative follow-up visits between 1 and 6 months after surgery. These data were subsequently extracted retrospectively from medical records for analysis. Study population The target population for this study included all patients presenting with intracranial tumors requiring surgical intervention. The source population was defined as patients operated for glioblastoma at the Yaoundé General Hospital between January 2018 and June 2025, with histopathological confirmation of the diagnosis. Eligible participants were those who had undergone surgical resection for glioblastoma within the specified period and had available histopathological proof of glioblastoma. Patients whose medical records could not be retrieved or were incomplete were excluded from the study. Sample size and sampling procedure The sampling procedure was consecutive and exhaustive. This meant that all eligible patients who met the inclusion criteria during the study period were systematically included. The approach ensured a representative cohort by minimizing selection bias and capturing all surgically managed cases of glioblastoma over the specified timeframe. Data collection and variables Data collection was carried out through structured questionnaires, review of medical records, and clinical interviews. A preestablished technical sheet was used to record patient information. The variables collected included sociodemographic data such as age, sex, occupation, educational level, and region of origin. Medical history focused on comorbid conditions such as diabetes, hypertension, and exposure to ionizing radiation. Clinical data captured the presence of syndromes such as intracranial hypertension, irritative manifestations, or neurological deficits. Paraclinical information included the type of imaging performed, tumor localization, number of lesions, and associated abnormalities. Surgical data included the date of operation and the extent of resection. Histopathological findings were categorized into IDH-wildtype glioblastoma, IDH-mutant glioblastoma, or inconclusive GBM. According to the 2021 WHO Classification of Tumors of the Central Nervous System, a diagnosis of glioblastoma requires confirmation of IDH-wildtype status. In our cohort, molecular testing was performed in 4 out of 32 patients (12.5%) due to financial limitations restricting overseas molecular analysis. For the remaining patients without molecular characterization, tumors were classified as “Glioblastoma, NOS (Not Otherwise Specified)” in accordance with WHO 2021 terminology. Molecular and immunohistochemical markers analyzed included MGMT, alpha thalassemia/mental retardation X-linked, epidermal growth factor receptor, and IDH mutation status. Additional data were collected on adjuvant treatments such as radiotherapy and chemotherapy. Outcomes included QoL as measured by standardized scales, complications, postoperative neurological deficits, and survival data, including date of death. Overall survival was defined as the time interval between the date of histopathological confirmation of glioblastoma and the date of death or last follow-up. Data collection tools The principal tool for assessing QoL was the EORTC QLQ-C30.[15] This internationally validated instrument is specifically designed for cancer patients and measures multiple dimensions of health-related QoL. It consists of 30 items grouped into five functional scales (physical, role, cognitive, emotional, and social functioning), three symptom scales (fatigue, pain, and nausea/vomiting), a global health status/QoL scale, and several single items assessing additional symptoms such as insomnia, appetite loss, constipation, diarrhea, and financial difficulties. Scores are linearly transformed to a 0–100 scale, where higher functional scores and global health status scores indicate better QoL, while higher symptom scores indicate greater symptom burden. The French version of the questionnaire was used, as it has been validated and adapted for francophone populations, and it was pretested among a pilot sample to ensure contextual relevance and comprehension. In addition to the EORTC QLQ-C30, medical records provided data on demographics, comorbidities, clinical characteristics, surgical details, postoperative complications, and adjuvant treatments. Clinical interviews were conducted to assess residual symptoms and functional recovery when data were not available in the medical records. Secondary materials, including systematic reviews, journal articles, meta-analyses, and theses, were used as references to strengthen the research process. Logistical tools such as laptops, internet access, USB drives, mobile phones, and stationery supported the data collection process. Ethical considerations The study protocol was submitted for review and approval by the Institutional Ethics and Research Committee of the Faculty of Medicine and Biomedical Sciences of the University of Yaoundé I. Following this, clearance was also obtained from the Ethics Committee of the Yaoundé General Hospital. All participants were fully informed about the objectives and procedures of the study, and informed consent was obtained in either written or verbal form before enrollment. To ensure confidentiality, data were anonymized, coded, and securely stored with restricted access granted only to the research team. Risks to participants were minimal but included potential fatigue during completion of questionnaires and emotional distress during interviews. These were mitigated by supportive interactions and the option to withdraw from the study at any point without consequence. QoL assessment QoL was assessed using the Karnofsky Performance Status (KPS) and the EORTC QLQ-C30 questionnaire. The questionnaire was interviewer-administered during postoperative follow-up visits between 1 and 6 months after surgery. Missing data were managed according to EORTC scoring guidelines. Due to significant attrition at later follow-up, the 1-month postoperative QoL assessment (n = 14) was predefined as the primary QoL endpoint of this study. The 6-month assessment (n = 10) is presented as exploratory data. Statistical analysis Statistical analysis was performed using the Statistical Package for the Social Sciences software version 20. Quantitative variables were expressed as means ± standard deviation when normally distributed or as medians with interquartile ranges when appropriate. Qualitative variables were expressed as frequencies and percentages. Comparisons between categorical variables were performed using the Chi-square test or Fisher’s exact test when required. P < 0.05 was considered statistically significant. Overall survival was defined as the time interval between the date of histopathological confirmation of glioblastoma and the date of death or last follow-up. Survival analysis was performed using Kaplan–Meier survival curves. Comparisons between survival curves were primarily conducted using the log-rank test. The Breslow (Generalized Wilcoxon) test was used as a secondary exploratory analysis, giving more weight to early survival differences. Due to the limited sample size and the low number of events, multivariate logistic regression and Cox proportional hazards analyses were not performed to avoid model instability and unreliable estimates. Consequently, survival outcomes were reported using median survival with 95% confidence intervals (CI), which is more appropriate for Kaplan–Meier survival data. RESULTS Demographic data and clinical characteristics A total of 32 patients were included, representing 5.1% of the 622 intracranial tumor surgeries performed during the study period at the Yaoundé General Hospital. The median age was 47.50 years (17.75; 59.75), and the mean age was 42.9 ± 13.8 years. The extremes were 1–73 years. The most affected age group was 41–60 years (46.9%) [Figure 1]. There was a female predominance, with 21 women (65.6%) and 11 men, yielding a sex ratio of males to females of 0.52. Distribution of the population according to age. Neurologic deficit was the most frequent presenting symptom, observed in 22 patients (68.8%), followed by signs of intracranial hypertension (43.7%) and generalized seizures (37.5%). The average time from onset of symptoms to consultation was 2.4 months. Hemiparesis was present in 65.6% of patients, with aphasia in 15.6% and visual impairment in 25%. Neuroimaging and tumor characteristics Magnetic resonance imaging (MRI) was performed in 19 patients (59.4%) and computed tomography (CT) in the remaining 13 (40.6%). Lesions were hypointense on T1, hyperintense on T2, with ring enhancement after gadolinium in most cases. Tumor location was predominantly temporal (30.8%), followed by frontal (23.1%) and parietal lobes (15.4%). Right-sided involvement was noted in 59.4% of cases. One patient had bilateral lesions. Histopathology and molecular data Molecular testing was performed in a limited number of patients due to financial and logistical constraints related to sample shipment abroad. Among the 32 patients included in the study, only 4 underwent molecular analysis. Of these, an IDH mutation was identified in one patient, whereas three patients were classified as IDH-wildtype. The IDH status was unknown in the remaining 28 patients (87.5%). In accordance with the WHO 2021 criteria, cases without molecular testing were classified as “Glioblastoma, NOS.” Treatment modalities All patients underwent surgical resection. Among them, 18 patients (56.3%) had surgery alone, 6 (18.7%) had surgery followed by radiotherapy, and 8 (25%) received surgery plus adjuvant radiochemotherapy according to the Stupp protocol. The average time between surgery and adjuvant therapy initiation was 4.5 weeks. Survival outcomes Seventeen patients had complete follow-up data available for survival analysis. The median overall survival was 10.2 months (95% CI: 6.6–13.9). Survival varied according to therapeutic modalities. Patients treated with surgery alone had a median survival of 4.9 months (95% CI: 0.7–9.2), whereas those who received surgery followed by radiotherapy had a median survival of 12.5 months (95% CI: 5.1–19.9). Patients who benefited from the full multimodal treatment combining surgery, radiotherapy, and chemotherapy showed the longest median survival of 13.4 months (95% CI: 8.0–18.8). QoL data were available for 32 patients preoperatively and at discharge, 14 patients at 1 month, and 10 patients at 6 months, representing a 69% attrition rate from baseline to 6 months. Kaplan–Meier survival curves demonstrated improved survival among patients receiving combined therapeutic strategies [Figure 2]. Survival comparison using the log-rank test showed a statistically significant difference between treatment groups (P = 0.03). The Breslow (Generalized Wilcoxon) test showed a borderline difference (P = 0.058), likely reflecting early survival similarities between groups. Due to the limited sample size and low number of events, multivariate survival analysis was not performed to avoid unreliable estimates. Kaplan–Meier survival curve of patients operated on for glioblastomas. Correlations between variables and mortality Several correlations were analyzed: Age over 40 showed a trend toward increased mortality, although not statistically significant in multivariate analysis. Presence of comorbidities was not significantly associated with increased risk of death [Table 1]. Table 1:Correlation between sociodemographic characteristics and mortality. Correlation between sociodemographic characteristics and mortality. Tumor location did not significantly influence survival [Table 2]. Table 2:Correlation between tumor location and mortality. Correlation between tumor location and mortality. A better general condition at presentation (as assessed by KPS) was associated with lower mortality [Table 3]. Table 3:Correlation between general health conditions and mortality. Correlation between general health conditions and mortality. Patients receiving combined treatment had better QoL scores and longer survival compared to those receiving surgery alone. The median overall survival was 4.9 months (95% CI: 0.6–9.1) for patients who underwent surgery alone, compared to 13.4 months (95% CI: 8–18.8) for those who received adjuvant radiochemotherapy (P = 0.03, log-rank test) [Tables 4 and 5]. Table 4:Median survival according to the different therapeutic modalities. Median survival according to the different therapeutic modalities. Table 5:Overall statistical comparison. Overall statistical comparison. Differences between tests are explained by the Breslow test giving greater weight to early events. QoL scores QoL was evaluated using the KPS and EORTC QLQ-C30: The mean Karnofsky score among all patients was 68.75%, with higher scores observed in patients receiving multimodal treatment [Figure 3]. General condition according to the Karnofsky score. The average EORTC QLQ-C30 global health status score was 67.27% among survivors [Figure 4]. Quality of life according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. EORTC before surgery n = 32; EORTC after surgery n = 32; EORTC 1 month after surgery n = 14, and EORTC 6 month after n = 10 (after surgery and radiotherapy n = 3; after surgery and radiochemotherapy n = 7) [Table 6]. Table 6:Flow of quality-of-life assessment (QOL) and attrition at each time point. Flow of quality-of-life assessment (QOL) and attrition at each time point. DISCUSSION Demographic and clinical characteristics In our study, the mean age of patients operated on for glioblastoma was 42.9 years, with a median of 47.5 years. This age is significantly lower than the average age reported in developed countries, where glioblastoma predominantly affects patients over 60 years. However, our findings are consistent with those of Haman et al. in Cameroon, who also reported a younger population.[9] This may reflect demographic differences or delayed diagnosis in older populations with limited access to neurosurgical care. Females were more represented in our series (65.6%), contrasting with global epidemiology that typically shows a male predominance.[4,18] The unexpected female predominance observed in our study may reflect referral or sampling biases rather than a true epidemiological trend. It is possible that women were more likely to seek care at our center or to be referred for surgery, whereas some male patients may have received treatment elsewhere or remained undiagnosed. The most frequent clinical presentation was neurological deficit (68.8%), followed by signs of intracranial hypertension (56.3%). These results align with previous studies that identified neurological deficits as common presenting symptoms in glioblastoma.[1,23] Symptom duration before consultation was an average of 3.5 months, similar to findings from African studies.[13,18] This suggests delayed access to specialized care, often due to financial constraints or diagnostic limitations. Comorbidities were present in about one-third of patients, mainly hypertension and diabetes, but were not significantly associated with prognosis. Paraclinical and histopathological characteristics MRI was the most used imaging modality (59.4%), followed by CT scan (40.6%), consistent with modern diagnostic standards.[19] The most frequent tumor location was the temporal lobe (30.8%), corroborating studies by Gilard et al. and Sasmita et al., who highlighted a predilection for temporal and frontal regions.[7,18] This can be explained by the fact that these regions have a high density of astrocytes and oligodendrocytes, which provide a large pool of susceptible cells for malignant transformation. Histological analysis confirmed all cases as glioblastoma, with 4 patients benefiting from molecular profiling. Among them, one had IDH-mutated tumors, in agreement with the WHO 2021 classification, which defines glioblastoma IDH-wildtype as the standard entity.[4-6] The limited use of biomolecular markers reflects the challenges in resource-limited settings, as noted by Djientcheu et al.[3] Limitations of biomolecular testing access and its clinical impact Limited access to biomolecular testing, including MGMT promoter methylation, IDH1/2, and 1p/19q status, represents a significant constraint in our setting. Without these analyses, clinicians cannot fully stratify patients or tailor therapies according to molecular profiles, potentially affecting treatment decisions and survival outcomes. Expanding access to such testing could improve individualized care and prognostication for glioblastoma patients. Therapeutic modalities Surgical treatment was performed in all cases. Surgery alone was the most frequent approach (56.3%), followed by surgery with radiotherapy (18.8%) and surgery with chemoradiotherapy (25%). The role of maximal safe resection is well established in the literature and has been associated with improved survival.[18] The benefit of multimodal therapy, particularly the Stupp protocol, has been widely demonstrated.[7,18] Our results confirm this: patients who received surgery followed by chemoradiotherapy had a longer mean survival (13.4 months) (95% CI: 8–18.8) compared to those treated with surgery alone (4.9 months) (95% CI: 0.6–9.1) (P = 0.03, log-rank test), similar to findings by Stupp et al.[21] However, access to adjuvant therapies remains limited in our context, due to financial and infrastructural barriers. This underlines the need for policies to facilitate access to radiotherapy and temozolomide in Sub-Saharan Africa. Access to adjuvant therapies, such as temozolomide chemotherapy and radiotherapy, remains limited in our setting. Many patients can only undergo surgery alone, which reduces overall survival. Furthermore, molecular testing is not routinely performed, making personalized treatment difficult. These factors contribute to a median survival that is lower than that reported in high-resource countries. QoL and survival outcomes The average Karnofsky score at follow-up was 68.75, and the EORTC QLQ-C30 global health score was 67.27, indicating moderate functional autonomy. These results are comparable to those of Chen et al., who reported improved QoL in patients treated with complete multimodal protocols .[2] Survival analysis showed a mean overall survival of 10.2 months, which increased to 13.4 months in patients receiving the full treatment protocol. This is close to the global average of 14–16 months described in the literature,[10,22]demonstrating that, despite resource limitations, favorable outcomes can be achieved with standardized care. The substantial attrition observed at 6 months introduces a significant risk of survivor bias. Patients who completed the 6-month QoL assessment were necessarily alive and generally in relatively better clinical condition, which may have led to an overestimation of long-term QoL outcomes. Correlations and prognostic factors In our analysis, age over 40 years was associated with increased mortality, in line with prior studies highlighting age as a major prognostic factor.[17] No significant association was found between sex or comorbidities and mortality, consistent with previous data.[14] The type of treatment received was strongly correlated with survival and QoL. Patients treated with surgery plus chemoradiotherapy had significantly better outcomes, a trend observed globally.[14] KPS was also predictive of survival, as confirmed by prior publications.[25] Tumor location was not significantly associated with prognosis in our study, a finding that remains debated in the literature.[12] Limitations This study has several limitations. First, the relatively small sample size reduces statistical power and limits the ability to perform reliable multivariate analyses. Second, the retrospective cohort design exposes the study to potential information and selection biases. Third, molecular data were incomplete because of financial and logistical barriers to advanced testing, limiting tumor biological characterization. The absence of molecular characterization in the majority of patients (87.5%), prevented strict classification of IDH-wildtype glioblastoma according to the WHO 2021 criteria. This may limit comparability with contemporary molecularly defined cohorts. Fourth, QoL assessment was only possible in patients attending postoperative follow-up visits, introducing potential selection bias. Finally, access to adjuvant therapies such as radiotherapy and chemotherapy remains limited in our setting, which may have influenced survival outcomes. Referral patterns and healthcare access disparities may also explain the observed female predominance in our cohort. The 6-month QoL data (n = 10) are insufficient to draw reliable conclusions regarding long-term QoL and should therefore be interpreted with extreme caution. CONCLUSION Glioblastoma affects all ages in our setting. Most patients consulted late, with neurological deficits and signs of intracranial hypertension being the predominant clinical features. MRI was the most used imaging modality, although its accessibility remains limited for many patients. Surgical resection remains the cornerstone of treatment. However, access to adjuvant therapies such as radiotherapy and temozolomide was limited, influencing overall survival. Patients who received multimodal treatment, particularly surgery followed by chemoradiotherapy, had better survival outcomes and improved QoL. Despite significant resource constraints, our study demonstrates that with timely diagnosis and standardized treatment, outcomes comparable to global benchmarks can be achieved. Strengthening diagnostic capabilities, improving access to radiochemotherapy, and adopting a multidisciplinary approach are essential for optimizing the prognosis of glioblastoma in Sub-Saharan Africa.